Arai Heii, Sumitomo Kenta, Sakata Yukinori, Daidoji Kasumi, Takase Takao, Toyoda Tetsumi
Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Eisai Co., Ltd., Tokyo, Japan.
Psychogeriatrics. 2016 Mar;16(2):107-15. doi: 10.1111/psyg.12130. Epub 2015 Jun 26.
There have been very few long-term studies involving a large study population; existing studies usually have no more than a few hundred patients with Alzheimer's disease. For these reasons, there are no detailed investigations regarding changes in activities of daily living evaluated by the Functional Assessment Staging Test (FAST).
A long-term, large-scale observational study of donepezil hydrochloride (Aricept(®); Eisai Co., Ltd, Tokyo, Japan) is currently in progress. Its objective is to investigate disease state changes associated with the long-term administration of this drug and its safety in patients with Alzheimer's disease. In this report, data collected over a maximum of 24 months were compiled. Efficacy was assessed using FAST and a cognitive function test (Mini-Mental State Examination or the Hasegawa's Dementia Scale-Revised).
The percentages of patients whose FAST stage improved or remained the same compared to at the start of donepezil hydrochloride administration (baseline) were 91.1% at 6 months, 83.0% at 12 months, 79.5% at 18 months, and 74.8% at 24 months. Multivariate logistic regression analysis was conducted to investigate factors that affect the improvement and maintenance or exacerbation of FAST at 24 months. 'Independence level in the daily life of elderly with dementia' and 'duration of illness' were identified as variables that affected the improvement and maintenance or exacerbation of FAST. Cognitive function improved significantly at 12 weeks and at 6 months compared to baseline, maintained baseline levels at 12 months and at 18 months, and decreased significantly at 24 months compared to baseline.
This is the largest prospective study involving Alzheimer's disease patients in Japan, and we believe it is an important study that shows the reality of daily clinical practice.
涉及大量研究人群的长期研究非常少;现有研究通常只有不超过几百名阿尔茨海默病患者。由于这些原因,目前尚无关于通过功能评估分期测试(FAST)评估的日常生活活动变化的详细调查。
一项关于盐酸多奈哌齐(安理申(®);日本东京卫材株式会社)的长期、大规模观察性研究正在进行中。其目的是调查该药物长期给药相关的疾病状态变化及其在阿尔茨海默病患者中的安全性。在本报告中,汇总了最长24个月收集的数据。使用FAST和认知功能测试(简易精神状态检查表或修订版长谷川痴呆量表)评估疗效。
与开始服用盐酸多奈哌齐时(基线)相比,FAST分期改善或保持不变的患者百分比在6个月时为91.1%,12个月时为83.0%,18个月时为79.5%,24个月时为74.8%。进行多变量逻辑回归分析以调查影响24个月时FAST改善、维持或恶化的因素。“痴呆老年人日常生活中的独立水平”和“病程”被确定为影响FAST改善、维持或恶化的变量。与基线相比,认知功能在12周和6个月时显著改善,在12个月和18个月时维持在基线水平,在24个月时与基线相比显著下降。
这是日本涉及阿尔茨海默病患者的最大规模前瞻性研究,我们认为这是一项重要研究,展示了日常临床实践的实际情况。